Endocrinopathies induced by immune check point inhibitors. Optimal patient management tactics
- Authors: Khamnueva L.Y.1, Sergeeva K.A1, Andreeva L.S1, Davydova A.V1
-
Affiliations:
- Irkutsk State Medical University
- Issue: Vol 27, No 12 (2020)
- Pages: 8-13
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312913
- DOI: https://doi.org/10.18565/pharmateca.2020.12.8-13
- ID: 312913
Cite item
Abstract
Full Text
![Restricted Access](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
About the authors
Larisa Yu. Khamnueva
Irkutsk State Medical University
Email: hamnueval@mail.ru
Dr. Sci. (Med.), Professor, Head of the Department of Endocrinology, Clinical Pharmacology and Immunology 1, Krasnogo Vosstaniya str., Irkutsk 664003, Russian Federation
K. A Sergeeva
Irkutsk State Medical UniversityIrkutsk, Russia
L. S Andreeva
Irkutsk State Medical UniversityIrkutsk, Russia
A. V Davydova
Irkutsk State Medical UniversityIrkutsk, Russia
References
- Illouz F., Briet C., Cloix L., et al. Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists. Cancer Med. 2017;6(8):1923-29. doi: 10.1002/cam4.1145.
- Gonzàlez-Rodrfguez E., Rodrfguez-Abreu D. Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events. Oncologist. 2016;21(7):804-16. Doi: 10.1634/ theoncologist.2015-0509.
- Barroso Sousa R., Barry W.T., Garrido-Castro A.C., et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis. JAMA. Oncol. 2018;4(2):173-82. doi: 10.1001/jamaoncol.2017.3064.
- Tan M.H., Ravi I., Mizokami-Stout K., et al. Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports. Clin Diabet. Endocrinol. 2019;5:1. doi: 10.1186/s40842-018-0073-4.
- Dillard T., Yedinak C.G., Alumkal J., et al. Anti-CTIA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary. 2010;13(1):29-38. doi: 10.1007/s11102-009-0193-z.
- Yang J.C., Hughes M., Kammula U., et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007; 30(8):825-30.
- Blansfield J.A., Beck K.E., Tran K., et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 2005;28(6):593-98.
- Min L., Vaidya A., Becker C. Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series. Endocr Pract. 2012;18:351-55. doi: 10.4158/EP11273.OR.
- Faje A.T., Sullivan R., Lawrence D., et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014;99(11):4078-85. doi: 10.1210/jc.2014-2306.
- Kim Y.H., Lee B.J., Lee K.J. A case of pituitary metastasis from breast cancer that presented as left visual disturbance. J Korean Neurosurg Soc. 2012;51:94-7. doi: 10.3340/jkns.2012.51.2.94.
- Juszczak A., Gupta A., Karavitaki N. Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: A case report and review. Eur J Endocrinol. 2012;167:1-5. doi: 10.1530/EJE-12-0167.
- Lammert A., Schneider H.J., Bergmann T. Hypophysitis caused by ipilimumab in cancer patients: Hormone replacement or immunosuppressive therapy. Exp Clin Endocrinol Diabet. 2013;121:581-87. doi: 10.1055/s-0033-1355337.
- European Medicines Agency: Keytruda. EPAR. 2015. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/ medicines/003820/human_med_001886. jsp&mid=WC0b01ac058001d124. Accessed: April 14, 2016.
- Albarel F., Gaudy C., Castinetti F. Long-term followup of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol. 2015;172:195-204. doi: 10.1530/EJE-14-0845.
- Weber J.S., Gibney G.T., Yu B., et al. Survival, biomarker, and toxicity analysis of nivoiumab (NIVO) in patients that progressed on ipilimumab (IPI). J Clin Oncol. 2015;33(Suppl. 15):9055a. Doi: 10.1200/ jco.2015.33.15_suppl.9055.
- Torino F, Corsello S.M., Salvatori R. Endocrinological side-effects of immune checkpoint inhibitors. Curr Opin Oncol. 2016;28(4):278-87. doi: 10.1097/CC0.0000000000000293.
- Sznol M, Postow M.A., Davies M.J., et al. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treat Rev. 2017;58:70-6. doi: 10.1016/j.ctrv.2017.06.002.
- Rosenkranz A.A., Slastnikova T.A., Durymanov M.O., et al. Malignant melanoma and melanocortin 1 receptor. Biochem (Mosc). 2013;78:1228-37. doi: 10.1134/S0006297913110035.
- Abdel-Malek Z.A., Knittel J., Kadekaro A.L., et al. The melanocortin 1 receptor and the UV response of human melanocytes - a shift in paradigm. Photochem Photobiol. 2008;84:501-8. doi: 10.1111/j.1751-1097.2008.00294.x.
- Harsch I.A. Hypothesis: does adrenalitis caused by immune checkpoint-inhibitors put melanoma patients at an elevated risk for recurrence? J Immunother Cancer. 2019;7:166. https://doi.org/10.1186/s40425-019-0651-8.
- Hägg E, Asplund K., Lithner F. Value of basal plasma cortisol assays in the assessment of pituitary-adrenal insufficiency. Clin Endocrinol. (Oxf). 1987;26:221-26. doi: 10.1111/j.1365-2265.1987.tb00780.x.
- Falorni A., Laureti S., De Bellis A., et al. Italian addison network study: Update of diagnostic criteria for the etiological classification of primary adrenal insufficiency. J Clin Endocrinol Metab. 2004;89:1598-604. doi: 10.1210/jc.2003-030954.
- Purnell J.Q, Brandon D.D., Isabelle L.M., et al. Association of 24-hour cortisol production rates, cortisol-binding globulin, and plasma-free cortisol levels with body composition, leptin levels, and aging in adult men and women. J Clin Endocrinol Metab. 2004;89:281-87. doi: 10.1210/jc.2003-030440.
- de Miguel Novoa P, Vela E.T., Garcia N.P, et al. (Grupo Insuficiencia Adrenal). Guidelines for the diagnosis and treatment of adrenal insufficiency in the adult. Endocrinol Nutr. 2014;61(Suppl. 1):1-35. doi: 10.1016/S1575-0922(14)73526-0.
- Charmandari E., Nicolaides N.C., Chrousos G.P Adrenal insufficiency. Lancet. 2014;383:2152-67. doi: 10.1016/S0140-6736(13)61684-0.
- Wass J.A.H., Arlt W. How to avoid precipitating an acute adrenal crisis. BMJ. 2012;345:e6333. doi: 10.1136/bmj.e6333.
- Dine J., Gordon R., Shames Y., et al. Immune checkpoint inhibitors: an innovation in immunotherapy for the treatment and management of patients with cancer. Asia Pac J Oncol Nurs. 2017;4(2):127-35. doi: 10.4103/apjon.apjon_4_17.
- Morganstein D.L., Lai Z., Spain L., et al. Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clin Endocrinol. (Oxf). 2017;86(4):614-20. doi: 10.1111/cen.13297.
- Yonezaki K., Kobayashi T., Imachi H., et al. Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto's disease and diabetes mellitus: a case report. J Med Case Rep. 2018;12(1):171. doi: 10.1186/s13256-018-1708-x.
- Khan U., Rizvi H., Sano D., et al. Nivolumab induced myxedema crisis. J Immunother Cancer. 2017;5:13. doi: 10.1186/s40425-017-0213-x.
- Mehta R., Shah A., Almhanna K. Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: an evidence-based review of place in therapy. Onco Targ Ther. 2018:11:6525-37. doi: 10.2147/OTT.S152513.
- Robert C., Schachter J., Long G.V, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372:2521-32. doi: 10.1056/NEJMoa1503093.
- Kyriacou A., Melson E., Chen W., et al. Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus? Clin Med. (bond). 2020;20(4):417-23. doi: 10.7861/clinmed.2020-0054.
- Min L., Vaidya A., Becker C. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol. 2011;164:303-7. doi: 10.1530/EJE-10-0833.
- Garber J.R., Cobin R.H., Gharib H., et al. Clinical practice guidelines for hypothyroidism in adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract. 2012;18:988-1028. doi: 10.4158/EP12280.GL.
- Brahmer J.R., Tykodi S.S., Chow L.Q., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.NEngl J Med. 2012;366(26):2455-65. doi: 10.1056/NEJMoa1200694.
- Chia-Jen W., Feng-Cheng C., Chi-Hong C., et al. Protective Role of Programmed Death 1 Ligand 1 (PD-L1) in Nonobese Diabetic Mice. Diabet. 2008;57(7):1861-69. doi: 10.2337/db07-1260.
- de Filette J., Andreescu C.E., Cools F, et al. A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors. Horm Metab Res. 2019;51(3):145-56. doi: 10.1055/a-0843-3366.
- Stamatouli A.M., Quandt Z., Perdigoto A.L., et al. Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabet. 2018;67(8):1471-80. doi: 10.2337/dbi18-0002.
- Brahmer J.R., Lacchetti C., Schneider B.J. National Comprehensive Cancer Network (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714-68. doi: 10.1200/jco.2017.77.6385.
- National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) 5.0. Available at: https://ctep.cancer.gov/protocol_Development/electronic_applications/ctc.htm.
Supplementary files
![](/img/style/loading.gif)